ClinicalTrials.Veeva

Find clinical trials for Lymphoma in Taipei City

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Leukemia
Non-Hodgkin Lymphoma
Lymphoid Leukemia
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Cell Chronic Lymphocytic Leukemia

Lymphoma trials near Taipei City, TWN:

A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Participants With Follicular Lymphoma and Marginal Zone Lymphoma (OLYMPIA-5)

focused on patients who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come bac...

Enrolling
Marginal Zone Lymphoma (MZL)
Relapsed/Refractory Follicular Lymphoma
Drug: Rituximab
Drug: Lenalidomide

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Taipei City, Taiwan and 60 other locations

of CHO-H01 in subjects with relapsed/refractory CD20+ non-Hodgkin's lymphoma. It will also determine maximum tolerated dose (MTD) and recomm...

Enrolling
Non-Hodgkin Lymphoma
Biological: CHO-H01

Phase 1, Phase 2

Cho Pharma

Taipei, Taiwan and 7 other locations

The primary objective of this study is to determine the recommended dosing regimen of loncastuximab tesirine in diffuse large B-cell lymphoma...

Enrolling
High-grade B-cell Lymphoma
Diffuse Large B-Cell Lymphoma
Drug: Loncastuximab Tesirine

Phase 1

ADC Therapeutics

Taipei, Taiwan and 12 other locations

This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma...

Active, not recruiting
Relapsed/Refractory Peripheral T-Cell Lymphoma
Adult T Cell Leukemia/Lymphoma
Drug: Valemetostat Tosylate

Phase 2

Daiichi Sankyo

Taipei, Taiwan and 59 other locations

A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas...

Enrolling
EBV Associated Lymphoma
EBV Related Non-Hodgkin's Lymphoma
Drug: Nanatinostat in combination with valganciclovir

Phase 2

Viracta Therapeutics

Taipei City, Taiwan and 93 other locations

Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline immu...

Active, not recruiting
Non-Hodgkin Lymphoma
Drug: Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy
Drug: Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)

Phase 3

Novartis
Novartis

Taipei, Taiwan and 66 other locations

treatment of advanced classical Hodgkin lymphoma(HL)...

Active, not recruiting
Hodgkin Lymphoma
Drug: brentuximab vedotin
Drug: bleomycin

Phase 3

Takeda
Takeda

Taipei, Taiwan and 215 other locations

pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-0201 in adult patients with relapsed or refractory B-cell non-Hodgkin lymphoma...

Enrolling
B-cell Non Hodgkin Lymphoma
Drug: DR-0201

Phase 1

Dren Bio

Taipei, Taiwan and 7 other locations

or obinutuzumab) in subjects with relapsed or refractory (R/R) lymphoma. Subjects must have received at least 2 prior lines of therapy, and ...

Active, not recruiting
Lymphoma
Drug: Rituximab
Drug: CC-220

Phase 1

Celgene
Celgene

Taoyuan City, Taiwan and 25 other locations

safety, and tolerability BGB-3111 plus obinutuzumab versus obinutuzumab alone in participants with relapsed/refractory non-Hodgkin follicular lymphoma...

Active, not recruiting
Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
Drug: Obinutuzumab
Drug: Zanubrutinib

Phase 2

BeiGene
BeiGene

Taipei, Taiwan and 119 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems